Cargando…
The Prognostic Significance of Soluble Urokinase Plasminogen Activator Receptor in Acute Myeloid Leukemia
OBJECTIVE: The soluble urokinase plasminogen activator receptor (suPAR) is a soluble form of the urokinase plasminogen activator receptor expressed in various immune and cancer cells. The levels of suPAR have been demonstrated to correlate with prognosis in various cancers. This study was intended t...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Galenos Publishing
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5100725/ https://www.ncbi.nlm.nih.gov/pubmed/26376588 http://dx.doi.org/10.4274/tjh.2014.0405 |
_version_ | 1782466193540513792 |
---|---|
author | Erkut, Nergiz Menteşe, Ahmet Özbaş, Hasan Mücahit Ermantaş, Nilay Sümer, Ayşegül Örem, Asım Sönmez, Mehmet |
author_facet | Erkut, Nergiz Menteşe, Ahmet Özbaş, Hasan Mücahit Ermantaş, Nilay Sümer, Ayşegül Örem, Asım Sönmez, Mehmet |
author_sort | Erkut, Nergiz |
collection | PubMed |
description | OBJECTIVE: The soluble urokinase plasminogen activator receptor (suPAR) is a soluble form of the urokinase plasminogen activator receptor expressed in various immune and cancer cells. The levels of suPAR have been demonstrated to correlate with prognosis in various cancers. This study was intended to investigate serum suPAR levels and their effect on prognosis in patients with acute myeloid leukemia (AML). MATERIALS AND METHODS: Thirty newly diagnosed patients with AML and 29 healthy individuals were enrolled. Serum suPAR levels were analyzed by enzyme-linked immunosorbent assay. RESULTS: Serum suPAR levels were significantly higher in patients with AML than in healthy individuals (9±5.9 ng/mL and 2.4±1.4 ng/mL, respectively; p<0.001). Positive correlation was determined between suPAR levels and white blood cell counts (p<0.01). Serum suPAR levels were lower in patients who achieved complete response than in patients not achieving complete response (5.5±2.2 ng/mL and 12±6.6 ng/mL, respectively; p<0.001). The median overall survival was longer in patients with serum suPAR levels below 6.71 ng/mL than in those with serum suPAR levels above 6.71 ng/mL (12.6±13.2 months and 1.71±0.6 months, respectively; p=0.02). Multivariate Cox regression analysis showed that suPAR had independent prognostic value (95% confidence interval: 1.029-6.259; p<0.05) in AML. CONCLUSION: Serum suPAR levels can be used as a prognostic marker in AML. |
format | Online Article Text |
id | pubmed-5100725 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Galenos Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-51007252016-11-15 The Prognostic Significance of Soluble Urokinase Plasminogen Activator Receptor in Acute Myeloid Leukemia Erkut, Nergiz Menteşe, Ahmet Özbaş, Hasan Mücahit Ermantaş, Nilay Sümer, Ayşegül Örem, Asım Sönmez, Mehmet Turk J Haematol Research Article OBJECTIVE: The soluble urokinase plasminogen activator receptor (suPAR) is a soluble form of the urokinase plasminogen activator receptor expressed in various immune and cancer cells. The levels of suPAR have been demonstrated to correlate with prognosis in various cancers. This study was intended to investigate serum suPAR levels and their effect on prognosis in patients with acute myeloid leukemia (AML). MATERIALS AND METHODS: Thirty newly diagnosed patients with AML and 29 healthy individuals were enrolled. Serum suPAR levels were analyzed by enzyme-linked immunosorbent assay. RESULTS: Serum suPAR levels were significantly higher in patients with AML than in healthy individuals (9±5.9 ng/mL and 2.4±1.4 ng/mL, respectively; p<0.001). Positive correlation was determined between suPAR levels and white blood cell counts (p<0.01). Serum suPAR levels were lower in patients who achieved complete response than in patients not achieving complete response (5.5±2.2 ng/mL and 12±6.6 ng/mL, respectively; p<0.001). The median overall survival was longer in patients with serum suPAR levels below 6.71 ng/mL than in those with serum suPAR levels above 6.71 ng/mL (12.6±13.2 months and 1.71±0.6 months, respectively; p=0.02). Multivariate Cox regression analysis showed that suPAR had independent prognostic value (95% confidence interval: 1.029-6.259; p<0.05) in AML. CONCLUSION: Serum suPAR levels can be used as a prognostic marker in AML. Galenos Publishing 2016-06 2016-05-16 /pmc/articles/PMC5100725/ /pubmed/26376588 http://dx.doi.org/10.4274/tjh.2014.0405 Text en © Turkish Journal of Hematology, Published by Galenos Publishing. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Erkut, Nergiz Menteşe, Ahmet Özbaş, Hasan Mücahit Ermantaş, Nilay Sümer, Ayşegül Örem, Asım Sönmez, Mehmet The Prognostic Significance of Soluble Urokinase Plasminogen Activator Receptor in Acute Myeloid Leukemia |
title | The Prognostic Significance of Soluble Urokinase Plasminogen Activator Receptor in Acute Myeloid Leukemia |
title_full | The Prognostic Significance of Soluble Urokinase Plasminogen Activator Receptor in Acute Myeloid Leukemia |
title_fullStr | The Prognostic Significance of Soluble Urokinase Plasminogen Activator Receptor in Acute Myeloid Leukemia |
title_full_unstemmed | The Prognostic Significance of Soluble Urokinase Plasminogen Activator Receptor in Acute Myeloid Leukemia |
title_short | The Prognostic Significance of Soluble Urokinase Plasminogen Activator Receptor in Acute Myeloid Leukemia |
title_sort | prognostic significance of soluble urokinase plasminogen activator receptor in acute myeloid leukemia |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5100725/ https://www.ncbi.nlm.nih.gov/pubmed/26376588 http://dx.doi.org/10.4274/tjh.2014.0405 |
work_keys_str_mv | AT erkutnergiz theprognosticsignificanceofsolubleurokinaseplasminogenactivatorreceptorinacutemyeloidleukemia AT menteseahmet theprognosticsignificanceofsolubleurokinaseplasminogenactivatorreceptorinacutemyeloidleukemia AT ozbashasanmucahit theprognosticsignificanceofsolubleurokinaseplasminogenactivatorreceptorinacutemyeloidleukemia AT ermantasnilay theprognosticsignificanceofsolubleurokinaseplasminogenactivatorreceptorinacutemyeloidleukemia AT sumeraysegul theprognosticsignificanceofsolubleurokinaseplasminogenactivatorreceptorinacutemyeloidleukemia AT oremasım theprognosticsignificanceofsolubleurokinaseplasminogenactivatorreceptorinacutemyeloidleukemia AT sonmezmehmet theprognosticsignificanceofsolubleurokinaseplasminogenactivatorreceptorinacutemyeloidleukemia AT erkutnergiz prognosticsignificanceofsolubleurokinaseplasminogenactivatorreceptorinacutemyeloidleukemia AT menteseahmet prognosticsignificanceofsolubleurokinaseplasminogenactivatorreceptorinacutemyeloidleukemia AT ozbashasanmucahit prognosticsignificanceofsolubleurokinaseplasminogenactivatorreceptorinacutemyeloidleukemia AT ermantasnilay prognosticsignificanceofsolubleurokinaseplasminogenactivatorreceptorinacutemyeloidleukemia AT sumeraysegul prognosticsignificanceofsolubleurokinaseplasminogenactivatorreceptorinacutemyeloidleukemia AT oremasım prognosticsignificanceofsolubleurokinaseplasminogenactivatorreceptorinacutemyeloidleukemia AT sonmezmehmet prognosticsignificanceofsolubleurokinaseplasminogenactivatorreceptorinacutemyeloidleukemia |